Bufexamac - CAS 2438-72-4
Catalog number:
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
Molecular Weight:
Bufexamac is a COX inhibitor for IFN-α release with EC50 of 8.9 μM.Bufexamac is a drug used as an anti-inflammatory agent on the skin, as well as rectally. Common brand names include Paraderm and Parfenac. It was withdrawn in Europe because of allergic reactions.
Publictions citing BOC Sciences Products
  • >> More
1.Allergic contact dermatitis to topical preparations of bufexamac.
Pan Y1, Nixon R. Australas J Dermatol. 2012 Aug;53(3):207-10. doi: 10.1111/j.1440-0960.2012.00876.x. Epub 2012 Mar 2.
In Australia bufexamac is mainly used for pharmacist-initiated local treatment of various dermatoses. The European Medicines Agency's Committee for Medicinal Products for Human Use recently recommended that marketing authorisation for bufexamac-containing preparations be revoked throughout the European Union because of the risk of severe allergic contact dermatitis. We retrospectively reviewed the patch test database at the Skin and Cancer Foundation Inc. and identified 19 cases of positive reactions to bufexamac (5% petrolatum) from 451 people patch tested. The bufexamac reaction was deemed relevant to the presenting dermatitis in 13 of 19 (68%) patients. Bufexamac allergic contact dermatitis is under-reported in the English literature. We wish to emphasise the severity and the unusually polymorphic eruptions observed in some of the cases. Clinicians should consider the possibility of allergic contact dermatitis to bufexamac-containing preparations in all patients where there is a history of exposure, even if used for only a short time.
2.In vitro photobiochemical characterization of sulfobutylether-β-cyclodextrin formulation of bufexamac.
Seto Y1, Ochi M, Igarashi N, Inoue R, Oishi A, Toida T, Yamada S, Onoue S. J Pharm Biomed Anal. 2011 Jun 1;55(3):591-6. doi: 10.1016/j.jpba.2011.02.025. Epub 2011 Feb 26.
The present study aimed to modulate the photoreactivity of bufexamac, with a focus on photostability and phototoxicity, by forming an inclusion complex with sulfobutylether-β-cyclodextrin (SBECD). The photobiochemical properties of bufexamac were evaluated by reactive oxygen species (ROS) assay and using in vitro photogenotoxic assessment tools. To assess the inclusion properties of SBECD complex with bufexamac, a UV absorption spectroscopic study was also carried out. The influence of SBECD on the photoreactivity of bufexamac was analyzed by ROS assay and photostability test. From the photobiochemical data, superoxide generation from irradiated bufexamac indicated its photoreactivity; however, the photogenotoxic risk of bufexamac was negligible owing to low DNA-binding affinity and DNA-photocleaving activity. SBECD complex of bufexamac was formed, and the association constant of the complex was calculated to be 620M(-1). On the basis of the photochemical data on bufexamac co-existing with SBECD, ROS generation from irradiated bufexamac (200μM) was inhibited by SBECD at concentrations of over 20μM.
3.Bufexamac ameliorates LPS-induced acute lung injury in mice by targeting LTA4H.
Xiao Q1, Dong N2, Yao X2, Wu D2, Lu Y2, Mao F2, Zhu J2, Li J2, Huang J2, Chen A3, Huang L3, Wang X3, Yang G1, He G1, Xu Y3, Lu W4. Sci Rep. 2016 Apr 29;6:25298. doi: 10.1038/srep25298.
Neutrophils play an important role in the occurrence and development of acute lung injury (ALI). Leukotriene B4 (LTB4), a hydrolysis product of epoxide leukotriene A4 (LTA4) catalyzed by LTA4 hydrolase (LTA4H), is one of the most potent chemoattractants for neutrophil. Bufexamac is a drug widely used as an anti-inflammatory agent on the skin, however, the mechanism of action is still not fully understood. In this study, we found bufexamac was capable of specifically inhibiting LTA4H enzymatic activity and revealed the mode of interaction of bufexamac and LTA4H using X-ray crystallography. Moreover, bufexamac significantly prevented the production of LTB4 in neutrophil and inhibited the fMLP-induced neutrophil migration through inhibition of LTA4H. Finally, bufexamac significantly attenuated lung inflammation as reflected by reduced LTB4 levels and weakened neutrophil infiltration in bronchoalveolar lavage fluid from a lipopolysaccharide-induced ALI mouse model.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related COX Products

CAS 62-44-2 Phenacetin

(CAS: 62-44-2)

Phenacetin is a non-opioid analgesic without anti-inflammatory properties. It is a pain-relieving and fever-reducing drug and was withdrawn from the Canadian ma...

CAS 189954-96-9 Firocoxib

(CAS: 189954-96-9)

A selective COX-2 inhibitor

CAS 198470-84-7 Parecoxib

(CAS: 198470-84-7)

The prodrug Parecoxib as well as its active metabolite val have a specific affinity to the cannabinoid (CB) receptor measured in CB1-expressing HEK 293 cells an...

CAS 116686-15-8 FK 3311

FK 3311
(CAS: 116686-15-8)

A selective COX-2 inhibitor

CAS 123663-49-0 Iguratimod

(CAS: 123663-49-0)

Iguratimod(T-614) is a selective inhibitor of cyclo-oxygenase-2 (COX-2), and inhibits the production of interleukin-1 (IL-1), IL-6, IL-8 and tumour necrosis fac...

CAS 530-78-9 Flufenamic acid

Flufenamic acid
(CAS: 530-78-9)

Flufenamic Acid is an anti-inflammatory agent, and also acts as an ion channel modulator.

CAS 18524-94-2 Loganin

(CAS: 18524-94-2)

Loganin, isolated from the seeds of Strychnos nux-vomica, is an iridoid glycoside inhibitor of Cox-1 and it shows antioxidant, hepatoprotective, and neuroprotec...

CAS 120210-48-2 Tenidap

(CAS: 120210-48-2)

Tenidap is one of the nonsteroidal antiinflammatory drugs. It is a COX1/2 and 5-lipoxygenase inhibitor. Tenidap preferentially inhibits COX-1 and IC50 value is...

CAS 154355-75-6 COX/5-LO-IN-1

(CAS: 154355-75-6)

A dual inhibitor of cylooxygenase and 5-lipoxygenase

(CAS: 189699-82-9)

FR-188582, with anti-inflammatory and ulcerogenic properties, is a highly selective inhibitor of COX-2 with IC50= 0.017 microM.

CAS 15307-79-6 Diclofenac Sodium

Diclofenac Sodium
(CAS: 15307-79-6)

A non-selective COX inhibitor with IC50 of 0.5 μg/ml and 0.5 μg/ml for COX-1 and -2 in intact cells, respectively

CAS 50-78-2 Aspirin

(CAS: 50-78-2)

A salicylate and irreversible COX1 and COX2 inhibitor

CAS 158959-32-1 SC57666

(CAS: 158959-32-1)

A selective COX2 inhibitor (IC50= 26 nM)

CAS 64490-92-2 Tolmetin sodium dihydrate

Tolmetin sodium dihydrate
(CAS: 64490-92-2)

Tolmetin sodium dihydrate is a non-steroidal anti-inflammatory agent for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis.

PD 127443
(CAS: 121502-05-4)

This active molecular is a Leukotriene B4 antagonist. PD- 127443 is also a 5-lipoxygenase and cyclooxygenase inhibitor and it has been reported to have antiinfl...

CAS 2438-72-4 Bufexamac

(CAS: 2438-72-4)

Bufexamac is a COX inhibitor for IFN-α release with EC50 of 8.9 μM.Bufexamac is a drug used as an anti-inflammatory agent on the skin, as well as rectally. Comm...

CAS 169590-42-5 Celecoxib

(CAS: 169590-42-5)

A highly selective COX-2 inhibitor

(CAS: 197438-73-6)

BMS-347070 is a COX-2 inhibitor, initially developed for the treatment for Colorectal cancer.

CAS 51146-57-7 (R)-(-)-Ibuprofen

(CAS: 51146-57-7)

An inhibitor of Cox-1 and Cox-2;A nonsteroidal anti-inflammatory drug

CAS 41340-25-4 Etodolac

(CAS: 41340-25-4)

A non-selective inhibitor of COX

Chemical Structure

CAS 2438-72-4 Bufexamac

Quick Inquiry

Verification code

Featured Items